Current pharmaceutical design of antituberculosis drugs: Future perspectives

Current Pharmaceutical Design

Volumn 16, Issue 24, 2010, Pages 2656-2665

  Speck Planche, Alejandro ^a   Scotti, Marcus Tulius ^b   de Paulo Emerenciano, Vicente ^c  

^a UNIVERSIDAD DE ORIENTE   (Cuba)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

3D QSAR methodologies; Enzymatic inhibitors; Graph theoretical approaches; Ligand based drug design; Structure based drug design

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; 2,3 DIDEOXY HEX 2 ENOPYRANOSIDE DERIVATIVE; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; CERULENIN; COMPOUND 16; DINITRO ORTHO CRESOL; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENZYME INHIBITOR; GATIFLOXACIN; GYRASE INHIBITOR; IMIPENEM; ISONIAZID; LBK 611; N PHENYL 6 METHYL 2 OXO 4 PHENYL 1,2,3,4 TETRAHYDROPYRIMIDINE 5 CARBOXAMIDE; NITROFURANYLAMIDE DERIVATIVE; PENTAMIDINE; PEPTIDE DEFORMYLASE INHIBITOR; PHENANTHRENE DERIVATIVE; PLATENSIMYCIN; RESERPINE; SRI 3072; TRICLOSAN; TRIFLUOPERAZINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; COMPUTER-AIDED DESIGN; DOSAGE FORMS; DRUG DESIGN; FORECASTING; HUMANS; LIGANDS; MOLECULAR CONFORMATION; MYCOBACTERIUM TUBERCULOSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77957941198     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210792389289     Document Type: Article

References (101)

1. th ed. USA: Saunders Elsevier 2007.
2. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Eng J Med 2002; 347: 1860-66.
3. A world free of TB. World Health Organization Report. Available at: http://www.who.int/tb/en/, [cited 2010 Jan 5].
4. Estrada E. How the parts organize in the whole? A top-down view of molecular descriptors and properties for QSAR and drug design. Mini Rev Med Chem 2008; 8: 213-21.
5. Estrada E, Uriarte E, Vilar S. Effect of protein backbone folding on the stability of protein-ligand complexes. J Proteome Res 2006; 5: 105-11.
6. Estrada E. Protein bipartivity and essentiality in the yeast protein-protein interaction network. J Proteome Res 2006; 5: 2177-84.
7. Estrada E. Virtual identification of essential proteins within the protein interaction network of yeast. Proteomics 2006; 6: 35-40.
8. Randic M, Estrada E. Order from chaos: observing hormesis at the proteome level. J Proteome Res 2005; 4: 2133-6.
9. Fernández M, Caballero F, Fernández L, et al. Classification of conformational stability of protein mutants from 3D pseudo-folding graph representation of protein sequences using support vector machines. Proteins 2008; 70: 167-75.
10. Caballero J, Fernandez M. Artificial neural networks from MAT-LAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr Top Med Chem 2008; 8: 1580-605.
11. Fernández M, Caballero J, Fernández L, et al. Protein radial distribution function (P-RDF) and Bayesian-Regularized Genetic Neural Networks for modeling protein conformational stability: Chymotrypsin inhibitor 2 mutants. J Mol Graph Model 2007; 26: 748-59.
12. Fernández L, Caballero J, Abreu JI, et al. Amino acid sequence autocorrelation vectors and bayesian-regularized genetic neural networks for modeling protein conformational stability: gene V protein mutants. Proteins 2007; 67: 834-52.
13. Caballero J, Fernández L, Garriga M, et al. Proteometric study of ghrelin receptor function variations upon mutations using amino acid sequence autocorrelation vectors and genetic algorithm-based least square support vector machines. J Mol Graph Model 2007; 26: 166-78.
14. Duchowicz PR, Fernandez M, Caballero J, et al. QSAR for nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem 2006; 14: 5876-89.
15. Rodriguez-Soca Y, Munteanu CR, Dorado J, et al. Plasmod-PPI: A web-server predicting complex biopolymer targets in plasmodium with entropy measures of protein-protein interactions. Polymer 2010; 51: 264-73.
16. González-Díaz H, Munteanu CR, Eds. Topological Indices for Medicinal Chemistry, Biology, Parasitology, Neurological and Social Networks. Kerala: Transworld Research Network 2010.
17. González-Díaz H, Duardo-Sanchez A, Ubeira FM, et al. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr Drug Metabol 2010; 11: 379-406.
18. Vina D, Uriarte E, Orallo F, et al. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol Pharm 2009; 6: 825-35.
19. Rodriguez-Soca Y, Munteanu CR, Prado-Prado FJ, et al. Trypano-PPI: A web server for prediction of unique targets in trypano-some proteome by using electrostatic parameters of protein-protein interactions. J Proteome Res 2009; 9(2): 1182-90.
20. Pérez-Montoto LG, Prado-Prado F, Ubeira FM, et al. Study of parasitic infections, cancer, and other diseases with massspectrometry and quantitative proteome-disease relationships. Curr Proteomics 2009; 6: 246-61.
21. Munteanu CR, Vazquez JM, Dorado J, et al. Complex network spectral moments for ATCUN Motif DNA cleavage: first predictive study on proteins of human pathogen parasites. J Proteome Res 2009; 8: 5219-28.
22. González-Díaz H, Prado-Prado F, Pérez-Montoto LG, et al. QSAR models for proteins of parasitic organisms, plants and human guests: theory, applications, legal protection, taxes, and regulatory issues. Curr Proteomics 2009; 6: 214-27.
23. González-Díaz H, Ferino G, Munteanu CR, et al. In: Cho W, Ed. Protein graphs in cancer prediction. Springer Verlag 2009.
24. Concu R, Podda G, Uriarte E., et al. In: CTaR Collett, C.D., Ed. A new computational chemistry & complex networks approach to structure-function and similarity relationships in protein enzymes. USA: Nova Science Publishers 2009.
25. Concu R, Dea-Ayuela MA, Perez-Montoto LG, et al. Prediction of enzyme classes from 3D structure: a general model and examples of experimental-theoretic scoring of peptide mass fingerprints of Leishmania proteins. J Proteome Res 2009; 8: 4372-82.
26. Aguero-Chapin G, Varona-Santos J, de la Riva GA, et al. Alignment-free prediction of polygalacturonases with pseudofolding topological indices: experimental isolation from coffea arabica and prediction of a new sequence. J Proteome Res 2009; 8: 2122-28.
27. Gonzalez-Diaz H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008; 8: 1676-90.
28. González-Díaz H, González-Díaz Y, Santana L, et al. Proteomics, networks and connectivity indices. Proteomics 2008; 8: 750-78.
29. González-Díaz H, Vilar S, Santana L, et al. Medicinal chemistry and bioinformatics -current trends in drugs discovery with networks topological indices. Curr Top Med Chem 2007; 7: 1025-39.
30. González-Díaz H, Saiz-Urra L, Molina R, et al. A model for the recognition of protein kinases based on the entropy of 3D van der waals interactions. J Proteome Res 2007; 6: 904-08.
31. Gonzalez-Diaz H, Saiz-Urra L, Molina R, et al. Computational chemistry approach to protein kinase recognition using 3D stochastic van der Waals spectral moments. J Comput Chem 2007; 28: 1042-8.
32. González-Díaz H, Pérez-Castillo Y, Podda G, et al. Computational chemistry comparison of stable/nonstable protein mutants classification models based on 3D and topological indices. J Comput Chem 2007; 28: 1990-95.
33. Ivanciuc O. Drug design with artificial intelligence methods. In: Meyers RA, Ed. Berlin: Springer-Verlag 2009; pp. 2113-39.
34. Ivanciuc O. Drug design with artificial neural networks. In: Meyers RA, Ed. Berlin: Springer-Verlag 2009; pp. 2139-59.
35. Ivanciuc O. Drug design with machine learning. In: Meyers RA, Ed. Berlin: Springer-Verlag 2009; pp. 2159-96.
36. Ivanciuc O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr Top Med Chem 2008; 8: 1691-709.
37. Ivanciuc O, Oezguen N, Mathura VS, et al. Using property based sequence motifs and 3D modeling to determine structure and functional regions of proteins. Curr Med Chem 2004; 11: 583-93.
38. Hansch C, Leo A. Exploring QSAR: fundamentals and applications in Chemistry and Biology. Washington, DC: American Chemical Society 1995.
39. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006; 12: 4047-70.
40. Sanger Institute. Available at: http://www.sanger.ac.uk/Projects/M_tuberculosis/, 2007.
41. Brenda Database: The Comprehensive Enzyme Information System. Available at: http://www.brenda-enzymes.org/. 2010.
42. Aubry A, Pan XS, Fisher LM, et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-8.
43. Babaoglu K, Page MA, Jones VC, et al. Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett 2003; 13: 3227-30.
44. Chambers HF, Moreau D, Yajko D, et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 1995; 39: 2620-4.
45. Ferreras JA, Ryu JS, Di Lello F, et al. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol 2005; 1: 29-32.
46. Gerum AB, Ulmer JE, Jacobus DP, et al. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother 2002; 46: 3362-9.
47. Harth G, Horwitz MA. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets. J Exp Med 1999; 189: 1425-36.
48. He X, Alian A, Stroud R, et al. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem 2006; 49: 6308-23.
49. Kremer L, Dover LG, Morbidoni HR, et al. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem 2003; 278: 20547-54.
50. Kuo MR, Morbidoni HR, Alland D, et al. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 2003; 278: 20851-9.
51. Pichota A, Duraiswamy J, Yin Z, et al. Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. Bioorg Med Chem Lett 2008; 18: 6568-72.
52. Sivendran S, Jones V, Sun D, et al. Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorg Med Chem 2010; 18: 896908.
53. Sriram D, Aubry A, Yogeeswari P, et al. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorg Med Chem Lett 2006; 16: 2982-5.
54. Sullivan TJ, Truglio JJ, Boyne ME, et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 2006; 1: 43-53.
55. Teo JW, Thayalan P, Beer D, et al. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother 2006; 50: 3665-73.
56. White EL, Suling WJ, Ross LJ. et al. 2-Alkoxycarbonylamino-pyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother 2002; 50: 111-4.
57. Zhao Y, Bacher A, Illarionov B, et al. Discovery and development of the covalent hydrates of trifluoromethylated pyrazoles as riboflavin synthase inhibitors with antibiotic activity against Mycobacterium tuberculosis. J Org Chem 2009; 74: 5297-303.
58. Brown AK, Taylor RC, Bhatt A, et al. Platensimycin activity against mycobacterial beta-ketoacyl-ACP synthases. PLoS One 2009; 4: e6306.
59. Ayyadurai N, Kirubakaran SI, Srisha S, et al. Biological and molecular variability of Sarocladium oryzae, the sheath rot pathogen of rice (Oryza sativa L.). Curr Microbiol 2005; 50: 319-23.
60. Tretter EM, Schoeffler AJ, Weisfield SR, et al. Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. Proteins 2010; 78: 492-5.
61. Fu G, Wu J, Liu W, et al. Crystal structure of DNA gyrase B' domain sheds lights on the mechanism for T-segment navigation. Nucleic Acids Res 2009; 37: 5908-16.
62. Gowsia D, Babajan B, Chaitanya M, et al. In silico effective inhibition of galtifloxacin on built Mtb-DNA gyrase. JBSA 2009; 1: 50-55.
63. Wahab HA, Choong YS, Ibrahim P, et al. Elucidating isoniazid resistance using molecular modeling. J Chem Inf Model 2009; 49: 97-107.
64. ChEMBL Database. Available at: http://www.ebi.ac.uk/chembldb/, 2010.
65. Ventura C, Martins F. Application of quantitative structure-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family. J Med Chem 2008; 51: 612-24.
66. Andrade CH, Salum Lde B, Castilho MS, et al. Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents. Mol Divers 2008; 12: 47-59.
67. Saquib M, Gupta MK, Sagar R, et al. C-3 alkyl/arylalkyl-2,3-dideoxy hex-2-enopyranosides as antitubercular agents: synthesis, biological evaluation, and QSAR study. J Med Chem 2007; 50: 2942-50.
68. Sivakumar PM, Geetha Babu SK, Mukesh D. QSAR studies on chalcones and flavonoids as anti-tuberculosis agents using genetic function approximation (GFA) method. Chem Pharm Bull (Tokyo) 2007; 55: 44-9.
69. Imramovsky A, Vinsova J, Ferriz JM, et al. New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains. Bioorg Med Chem 2009; 17: 3572-9.
70. Virsodia V, Pissurlenkar RR, Manvar D, et al. Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxamides. Eur J Med Chem 2008; 43: 2103-15.
71. Shagufta, Kumar A, Panda G, et al. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents. J Mol Model 2007; 13: 99-109.
72. Raparti V, Chitre T, Bothara K, et al. Novel 4-(morpholin-4-yl)-N'-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations. Eur J Med Chem 2009; 44: 3954-60.
73. Nayyar A, Patel SR, Shaikh M, et al. Synthesis, anti-tuberculosis activity and 3D-QSAR study of amino acid conjugates of 4-(adamantan-1-yl) group containing quinolines. Eur J Med Chem 2009; 44: 2017-29.
74. Nayyar A, Malde A, Jain R., et al. 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents. Bioorg Med Chem 2006; 14: 847-56.
75. Manvar A, Malde A, Verma J, et al. Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-acetic acid benzylidene hydrazides. Eur J Med Chem 2008; 43: 2395-403.
76. Lu XY, Chen YD, Jiang YJ, et al. Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem 2009; 44: 3718-30.
77. Hevener KE, Ball DM, Buolamwini JK, et al. Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorg Med Chem 2008; 16: 8042-53.
78. Aparna V, Jeevan J, Ravi M., et al. 3D-QSAR studies on antitubercular thymidine monophosphate kinase inhibitors based on different alignment methods. Bioorg Med Chem Lett 2006; 16: 1014-20.
79. Manvar AT, Pissurlenkar RR, Virsodia VR, et al. Synthesis, in vitro antitubercular activity and 3D-QSAR study of 1,4-dihydropyridines. Mol Divers 2010; 14: 285-305.
80. Andrade CH, Pasqualoto KF, Ferreira EI., et al. 3D-Pharmacophore mapping of thymidine-based inhibitors of TMPK as potential antituberculosis agents. J Comput Aided Mol Des 2010; 24: 157-72.
81. Andrade CH, Pasqualoto KF, Ferreira EI, et al. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alphathymidine analogues as mycobacterial TMPK inhibitors. J Chem Inf Model 2009; 49: 1070-8.
82. Gupta RK, Thakur TS, Desiraju GR, et al. Structure-based design of DevR inhibitor active against nonreplicating Mycobacterium tuberculosis. J Med Chem 2009; 52: 6324-34.
83. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 2008; 41: 11-20.
84. Nordqvist A, Nilsson MT, Rottger S, et al. Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery. Bioorg Med Chem 2008; 16: 5501-13.
85. Tawari NR, Degani MS. Pharmacophore mapping and electronic feature analysis for a series of nitroaromatic compounds with antitubercular activity. J Comput Chem 2010; 31: 739-51.
86. Marrero-Ponce Y, Meneses-Marcel A, Rivera-Borroto OM, et al. Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds. J Comput Aided Mol Des 2008; 22: 523-40.
87. Marrero-Ponce Y, Khan MT, Casanola-Martin GM, et al. Bond-based 2D TOMOCOMD-CARDD approach for drug discovery: aiding decision-making in 'in silico' selection of new lead tyrosinase inhibitors. J Comput Aided Mol Des 2007; 21: 167-88.
88. Marrero Ponce Y, Cabrera Perez MA, Romero Zaldivar V, et al. A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci 2004; 7: 186-99.
89. Gonzalez-Diaz H, Torres-Gomez LA, Guevara Y, et al. Markovian chemicals in silico design (MARCH-INSIDE), a promising approach for computer-aided molecular design III: 2.5D indices for the discovery of antibacterials. J Mol Model 2005; 11: 116-23.
90. Gonzalez-Diaz H, Olazabal E, Santana L, et al. QSAR study of anticoccidial activity for diverse chemical compounds: prediction and experimental assay of trans-2-(2-nitrovinyl)furan. Bioorg Med Chem 2007; 15: 962-8.
91. Gonzalez-Diaz H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr Top Med Chem 2008; 8: 1554.
92. Galvez J, Garcia-Domenech R, De Julian-Ortiz V, et al. Topological approach to analgesia. J Chem Inf Comput Sci 1994; 34: 1198-203.
93. Galvez J, Garcia-Domenech R, de Julian-Ortiz JV, et al. Topological approach to drug design. J Chem Inf Comput Sci 1995; 35: 272-84.
94. Estrada E, Uriarte E. Recent advances on the role of topological indices in drug discovery research. Curr Med Chem 2001; 8: 1573-88.
95. Estrada E, Pena A. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem 2000; 8: 2755-70.
96. Estrada E, Delgado EJ, Alderete JB, et al. Quantum-connectivity descriptors in modeling solubility of environmentally important organic compounds. J Comput Chem 2004; 25: 1787-96.
97. Garcia-Garcia A, Galvez J, de Julian-Ortiz JV, et al. Search of chemical scaffolds for novel antituberculosis agents. J Biomol Screen 2005; 10: 206-14.
98. Speck Planche A, Scotti MT, Garcia Lopez A, et al. Design of novel antituberculosis compounds using graph-theoretical and substructural approaches. Mol Divers 2009; 13: 445-58.
99. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 1. Definition and applications for the prediction of physical properties of alkanes. J Chem Inf Comput Sci 1996; 36: 844-49.
100. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 2. Molecules containing heteroatoms and QSAR applications. J Chem Inf Comput Sci 1997; 37: 320-28.
101. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 3. Molecules containing cycles. J Chem Inf Comput Sci 1998; 38: 23-27.